CYP46A1 gene for the treatment of alzheimer's disease

US8198257B2 · kind B2 · utility

Assignee

• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR

Inventors

• Patrick Aubourg · Granville, US
• Nathalie Cartier-Lacave · Paris, FR
• Eloise Hudry · Paris, FR

Key dates

• Filing date: Sep 11, 2008
• Grant date: Jun 12, 2012
• Expiry date: Sep 11, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2750/14143
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a viral vector for treating Alzheimers disease, which vector comprises a cholesterol 24-hydroxylase (CYP46A1) encoding nucleic acid. In a preferred embodiment, the viral vector may be an Adeno-Associated-Virus (AAV) vector, preferably an AVV5 vector. The vector may be useful for the manufacture of a pharmaceutical composition for the treatment of Alzheimers disease in a subject, wherein the vector is to be administered directly into the brain of the subject or by intravenous or intrathecal injection.